Vanda Pharmaceuticals Leads 3 Promising Penny Stocks

As the U.S. markets navigate a volatile landscape marked by significant swings in major stock indexes, investors are increasingly seeking opportunities beyond the usual tech giants. Penny stocks, often representing smaller or newer companies, continue to pique interest despite their somewhat outdated label. These stocks can offer surprising value and potential growth when backed by strong financial health, making them an intriguing option for those looking to explore diverse investment avenues.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
Here Group (HERE)	$3.08	$271.92M	✅ 3 ⚠️ 1 View Analysis >
Dingdong (Cayman) (DDL)	$1.72	$370.75M	✅ 4 ⚠️ 0 View Analysis >
Waterdrop (WDH)	$1.58	$589.51M	✅ 4 ⚠️ 0 View Analysis >
LexinFintech Holdings (LX)	$3.39	$607.43M	✅ 4 ⚠️ 2 View Analysis >
FinVolution Group (FINV)	$4.77	$1.4B	✅ 4 ⚠️ 1 View Analysis >
Puma Biotechnology (PBYI)	$4.84	$246.16M	✅ 3 ⚠️ 3 View Analysis >
Performance Shipping (PSHG)	$2.12	$26.85M	✅ 4 ⚠️ 2 View Analysis >
CI&T (CINT)	$4.35	$560.81M	✅ 5 ⚠️ 0 View Analysis >
BAB (BABB)	$0.88614	$6.49M	✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT)	$3.71	$84.28M	✅ 3 ⚠️ 2 View Analysis >

Click here to see the full list of 365 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Vanda Pharmaceuticals (VNDA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for high unmet medical needs globally, with a market cap of approximately $303.76 million.

Operations: The company generates revenue from its Biotechnology (Startups) segment, amounting to $212.07 million.

Market Cap: $303.76M

Vanda Pharmaceuticals, with a market cap of approximately US$303.76 million, is navigating challenges typical of penny stocks. Despite being debt-free and having short-term assets exceeding liabilities, the company remains unprofitable with losses increasing over five years. Recent positive clinical trial results for tradipitant could bolster future prospects, pending FDA review by December 2025. However, revised earnings guidance and ongoing disputes with the FDA over generic approvals reflect operational hurdles. Vanda's strategic partnerships in sports media signal efforts to enhance brand visibility amidst financial volatility and trading below estimated fair value suggests potential undervaluation relative to peers.

• Take a closer look at Vanda Pharmaceuticals' potential here in our financial health report.
• Explore Vanda Pharmaceuticals' analyst forecasts in our growth report.

Agora (API)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Agora, Inc. operates a real-time engagement platform-as-a-service across the United States, China, and internationally, with a market cap of approximately $327.52 million.

Operations: Agora, Inc. does not report specific revenue segments.

Market Cap: $327.52M

Agora, Inc. has recently transitioned to profitability, reporting a net income of US$2.74 million for Q3 2025 compared to a loss the previous year. The company forecasts revenue growth of up to 10.1% for the fourth quarter, indicating positive momentum in its financial performance. Agora's integration with OpenAI's Realtime API enhances its platform capabilities, potentially expanding its market reach in conversational AI and real-time engagement sectors. Despite an inexperienced board and low return on equity at 0.8%, Agora's strong asset base and cash coverage of debt position it well within the penny stock landscape.

• Jump into the full analysis health report here for a deeper understanding of Agora.
• Review our growth performance report to gain insights into Agora's future.

CreateAI Holdings (TSPH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CreateAI Holdings Inc. is an artificial intelligence technology company specializing in video game and anime production and publishing, with a market cap of $96.59 million.

Operations: No specific revenue segments are reported for CreateAI Holdings Inc.

Market Cap: $96.59M

CreateAI Holdings Inc. remains a pre-revenue company with sales under US$1 million, reporting a net loss of US$7.89 million for Q3 2025. Despite financial challenges, the launch of Animon in China marks a significant milestone, positioning it as a leader in AI-generated anime content. Animon's innovative features cater to both amateur and professional creators, offering tools for high-quality production and cultural customization. However, the company's short cash runway and high share price volatility present risks typical of penny stocks, underscoring the importance of cautious consideration for potential investors interested in its growth prospects within the AI sector.

• Click to explore a detailed breakdown of our findings in CreateAI Holdings' financial health report.
• Assess CreateAI Holdings' previous results with our detailed historical performance reports.

Seize The Opportunity

• Click this link to deep-dive into the 365 companies within our US Penny Stocks screener.
• Searching for a Fresh Perspective? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com